Montis Biosciences Email Formats

Biotechnology Research • Leuven, Flemish Region, Belgium • 11-20 Employees

Montis Biosciences Email Formats

Montis Biosciences uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@montisbio.com), used 55.6% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@montisbio.com	55.6%
{first initial}{last name}	jdoe@montisbio.com	33.3%
{last name}{last name}	doedoe@montisbio.com	11.1%

Key Contact at Montis Biosciences

Gil Beyen

Chief Executive Officer

Company overview

Headquarters	Bio-Incubator 4 - Gaston Geenslaan 3, Heverlee, Flemish Region 3001, BE
Website	montisbio.com
NAICS	541714
Keywords	Oncology, Neuroinflammation, Neurodegeneration, Autoimmune Disorders
Founded	2020
Employees	11-20
Socials

About Montis Biosciences

Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers. Leveraging its patient-centric discovery platform, Montis is advancing unique and potent antibodies to bring new treatment options to those patients. Montis’ lead program, MB01, focuses on modulating the multifaceted roles of C1q, the activator of the classical complement pathway and a key immune system mediator in neuroinflammatory and autoimmune disorders. Unlike existing C1q-targeting approaches that focus on blocking the classical complement pathway, Montis has discovered novel anti-C1q antibodies, capable of targeting C1q’s complement-independent functions with or without inhibiting the classical complement cascade. These antibodies hold the potential to offer a paradigm shift in the complement field and to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies. Based on extensive in vitro end in vivo evaluation, Montis is working on selecting the drug candidates and aims to initiate two Phase 1 clinical trials in these indications in 1H 2026. Montis’ second program (MB02) focuses on inhibiting CD93, a novel perivascular target, in lung squamous cell carcinoma (LUSC). A potent drug candidate was selected, holding best-in-class potential in this inflammation-driven and underserved oncology indication. Montis plans to partner this promising asset. Montis is backed by a strong investor syndicate, including Droia Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB, and is led by a team with extensive drug development experience. Contact: info@montisbio.com Our website is currently in an updating phase.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

C-Suite

Manager

Employees by Department

Montis Biosciences has 3 employees across 3 departments.

Departments

Number of employees

Funding Data

Explore Montis Biosciences's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-07-14	9	$1,200,000

Funding Insights

$1,200,000

Total funding amount

$1,200,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Montis Biosciences is located in Leuven, Flemish Region, BE.

Montis Biosciences was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

Montis Biosciences has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Montis Biosciences has raised a total of $1,200,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Montis Biosciences

Gil Beyen

Chief Executive Officer

4.8

40,000 users